CTLA4 and rheumatoid arthritis: In a similar cross-sectional case–control study with rheumatoid arthritis patients [68], we examined the levels of serum sCD26 and DPP4 activity in patients’ groups defined according to the therapies (conventional or biological) with anti-TNF, anti-CD20, anti-IL6R, or Ig-CTLA4.